Biotech startup touts biomarker effect in PhI ALS study

A small Palo Alto, CA-based biotech has garnered some fresh attention for itself after touting the results of a small Phase I study designed to test its lead drug by measuring its impact on a key biomarker for Lou Gehrig's disease, or amyotrophic lateral sclerosis. While most developers focus their Phase I studies entirely on safety and tolerability, Neuraltus chose to also gauge the fluctuation of blood levels of the biomarker--which was not disclosed--24 hours after dosing. The developer, which the San Francisco Business Times notes is hoping to use the data to help woo new investors, recruited 32 patients for the study. Report

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.